A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Pancreatic Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (pancreatic cancer) 2) Participants must not have had any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic disease. Prior adjuvant therapy (including chemotherapy and/or radiotherapy) for pancreatic adenocarcinoma is permitted if neoadjuvant or adjuvant therapy was completed at least 6 months prior to study enrollment. Participants initially diagnosed with locally advanced pancreatic cancer who have undergone chemotherapy then resection and had no evidence of disease are eligible if relapse of metastatic disease has occurred and if the last dose of chemotherapy was received more than 6 months before study entry. 3) ECOG performance status of 0-1. 4) Availability of archival tissue or agree to undergo new biopsy of tumor lesion.

You may not be eligible for this study if the following are true:

  • 1) Underlying medical conditions that, in the Investigator’s or Sponsor’s opinion, will make the administration of investigational product hazardous. 2) History of a heart attack within the past 6 months, or history of a blood clot or stroke within the past 3 months. 3) Any active or documented history of autoimmune disease within the past 3 years, except for Type I Diabetes, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.